Cost-Effectiveness of Elbasvir/Grazoprevir Versus Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir (3D Regimen) for Treatment of Chronic Hepatitis C Genotype 1B Patients in China

MLA

PY Chen, et al. “Cost-Effectiveness of Elbasvir/Grazoprevir Versus Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir (3D Regimen) for Treatment of Chronic Hepatitis C Genotype 1B Patients in China.” Value in Health, vol. 21, Sept. 2018, p. S64. EBSCOhost, https://doi.org/10.1016/j.jval.2018.07.484.

APA

PY Chen, HC Li, A Ma, & Q Liu. (2018). Cost-Effectiveness of Elbasvir/Grazoprevir Versus Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir (3D Regimen) for Treatment of Chronic Hepatitis C Genotype 1B Patients in China. Value in Health, 21, S64. https://doi.org/10.1016/j.jval.2018.07.484

Chicago

PY Chen, HC Li, A Ma, and Q Liu. 2018. “Cost-Effectiveness of Elbasvir/Grazoprevir Versus Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir (3D Regimen) for Treatment of Chronic Hepatitis C Genotype 1B Patients in China.” Value in Health 21 (September): S64. doi:10.1016/j.jval.2018.07.484.